Luminophore-Labeled Molecules for Microarray Sensitivity

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current microarray-based assays face challenges in achieving high sensitivity and specificity, particularly in detecting rare clinical samples associated with hereditary hearing loss, due to interference from single-stranded DNA competing with surface-immobilized oligonucleotide probes during hybridization.

Innovation Solution

A method involving luminophore-labeling of target polynucleotides, denaturation to single-stranded form, coupling with particles, and binding to oligonucleotide probes on a microarray, combined with allele-specific PCR (ASPCR) using allele-specific and common primers with artificial mismatches, to enhance detection sensitivity and specificity.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If double-stranded DNA is used for hybridization with surface-immobilized oligonucleotide probes, then the assay can detect target polynucleotides, but the sensitivity and specificity are reduced due to interference from the non-target strand competing with probes

Engineering Contradiction:
Improvedetection accuracyVSAvoidinterference from non-target strand
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent extracts and removes the harmful non-target strand from the double-stranded DNA through denaturation, leaving only the single-stranded target DNA that can specifically hybridize with the oligonucleotide probes on the microarray, thereby eliminating the interference and improving detection accuracy

Inventive Principle:
Principle #2Taking out (Extraction)

Solution Approach 2:

The patent changes the physical state of the DNA from double-stranded to single-stranded by controlling the denaturation conditions (temperature, pH, or chemical agents), which transforms the DNA structure to eliminate the harmful non-target strand while preserving the target sequence for specific hybridization

Inventive Principle:
Principle #35Parameter changes

2Quantity of substance

If conventional PCR amplification is used, then target polynucleotides can be amplified, but sensitivity is insufficient for detecting rare clinical samples

Engineering Contradiction:
Improveamplification efficiencyVSAvoiddetection sensitivity
Core Design Contradiction:
Quantity of substanceVSReliability

Solution Approach 1:

The patent employs asymmetric PCR using unequal concentrations of forward and reverse primers, which creates an asymmetric amplification process that enriches for single-stranded DNA products with the specific orientation needed for microarray hybridization, thereby improving both amplification efficiency and detection sensitivity for rare clinical samples

Inventive Principle:
Principle #4Asymmetry

Solution Approach 2:

The patent performs preliminary asymmetric PCR amplification before the microarray hybridization step, which pre-enriches the target polynucleotides and prepares them in the optimal single-stranded form, thereby enhancing the sensitivity of subsequent detection in rare clinical samples

Inventive Principle:
Principle #10Preliminary action

3Measurement precision

If luminophore-labeled target polynucleotides are used, then detection sensitivity is improved, but the complexity of the assay protocol increases

Engineering Contradiction:
Improvedetection sensitivityVSAvoidassay protocol complexity
Core Design Contradiction:
Measurement precisionVSDevice complexity

Solution Approach 1:

The patent merges the labeling step with the PCR amplification process by incorporating luminophore-labeled nucleotides or primers into the asymmetric PCR reaction, thereby achieving both amplification and labeling in a single integrated step that improves detection sensitivity without proportionally increasing protocol complexity

Inventive Principle:
Principle #5Merging (Combining)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach significantly improves the sensitivity and specificity of microarray-based assays, enabling accurate detection of genetic mutations associated with hereditary hearing loss, even in rare clinical samples, by enriching single-stranded DNA and utilizing ASPCR for targeted amplification.

Implementation Method 1

luminophore-labeled molecules coupled with particles for microarray-based assays

Methodology Applied
Scientific EffectLuminescence: Luminescence

Implementation Method 2

magnetic bead labeling was employed so that assay results could be photographed

Methodology Applied
Scientific EffectMagnetism: Magnetism

Implementation Method 3

the double-stranded target polynucleotide is denatured to become single-stranded by a chemical reaction, an enzyme, heating, or a combination thereof

Methodology Applied
Scientific EffectDenaturation: Melting

Data Source

PatentEP2633067B1Luminophore-labeled molecules coupled with particles for microarray-based assays
Publication Date: 2023.06.28 CAPITALBIO CORP
  • EP2633067B1 patent drawingFigure 1
  • EP2633067B1 patent drawingFigure 2
  • EP2633067B1 patent drawingFigure 3

AI summary

A microarray-based assay is provided, which is used for analyzing molecular interactions, including polynucleotides, polypeptides, antibodies, small molecule compounds, peptides and carbohydrates. Such method comprises labeling a target molecule with a luminophore, coupling the target molecule to a particle, and binding to a probe molecule on microarray. In particular, multiplexed genetic analysis of nucleic acid fragments can be implemented. Specific genes, single nucleotide polymorphisms or gene mutations, such as deletions, insertions, and indels, can be identified. This technology, with high sensitivity, enables the detection and interpretation of molecular interactions in an efficient way.